Cas:7606-30-6 3-Phenylazetidine hydrochloride (1:1) manufacturer & supplier

Chemical Name:3-Phenylazetidine hydrochloride (1:1)

CAS.NO:7606-30-6

Synonyms:3-Phenylazetidine hydrochloride (1:1);3-phenyl-azetidine hydrochloride;3-phenylazetidine hcl;Azetidine, 3-phenyl-, hydrochloride (1:1)

Molecular Formula:C₉H₁₂ClN

Molecular Weight:169.651

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:12.03000

Exact Mass:169.065826

LogP:2.50420

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Phenylazetidine hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Azetidine, 3-phenyl-, hydrochloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-phenylazetidine hcl Use and application,3-Phenylazetidine hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 3-Phenylazetidine hydrochloride (1:1) manufacturer The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 3-Phenylazetidine hydrochloride (1:1) supplier With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs. 3-Phenylazetidine hydrochloride (1:1) vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 3-Phenylazetidine hydrochloride (1:1) factory The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.